Skip Navigation LinksHome > January 2014 - Volume 48 - Issue 1 > Novel Pharmacological Therapies for Management of Chronic Co...
Journal of Clinical Gastroenterology:
doi: 10.1097/01.mcg.0000436440.05887.02
Clinical Reviews

Novel Pharmacological Therapies for Management of Chronic Constipation

Gonzalez-Martinez, Marina A. MD*; Ortiz-Olvera, Nayeli X. MD, MSc; Mendez-Navarro, Jorge MD

Open Access
Collapse Box


Chronic constipation is a common health problem that significantly affects the quality of life of patients and impacts in terms of costs; current treatments based on fiber and laxatives cause dissatisfaction to doctors and patients in more than half of the cases. New drugs are now available or in very advanced stages of research, with different and innovative mechanisms of action as prucalopride, lubiprostone, and linaclotide. Prucalopride an enterokinetic, is a selective high-affinity 5-hydroxytryptamine (5-HT)4 receptor agonist of serotonin that increases the peristaltic reflex and the colonic contractions; lubiprostone, a type 2 chlorine channel activator, or linaclotide, a guanylate cyclase-C agonist of enterocytes, both prosecretory agents, stimulate the secretion of fluid within the intestinal lumen. In general, these promising drugs have proven efficacy and safety as a specific therapeutic option in patients with chronic constipation. Yet the solution might not be sufficient for everybody and still without the ideal drug that might be useful in all cases, the pharmacological revolution for colonic motility disorders has arrived.

© 2014 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.